---
title: "AOD-9604 Year-1 Outcomes From Real Users | HealthRX.com"
description: "A rigorous look at AOD-9604 (HGH fragment 176-191) year-1 user outcomes synthesized from Reddit, Drugs.com, and Trustpilot reports, set against available…"
url: https://healthrx.com/reviews-aod-9604/year-1-outcomes
publisher: HealthRX.com
---


HealthRX.com

Real-user reports on this peptide are mixed and mostly self-reported

[Print or save as PDF](https://healthrx.com/printables/reviews-aod-9604/year-1-outcomes?print=1)

[See the public record for AOD-9604](https://healthrx.com/data/aod-9604)

HealthRX.com quick answer. AOD-9604 (HGH fragment 176-191) is a synthetic peptide derived from amino acids 176 to 191 of human growth hormone. Clinical trials in humans never confirmed meaningful fat loss at any tested dose. Self-reported user data from Reddit, Drugs.com, and Trustpilot shows mixed results over 12 months, with most consistent responders combining the peptide with a caloric deficit and resistance training.

At a glance

- Drug name / AOD-9604 (HGH fragment 176-191), a 16-amino-acid C-terminal peptide of hGH
- Regulatory status / Not FDA-approved for any indication; classified as a research compound
- Studied human doses / 1 mg oral daily in the METAOD phase 2b trial (N=300+)
- Primary clinical finding / No statistically significant weight loss vs. Placebo at 12 weeks in METAOD-006
- Typical user-reported dose / 250 to 500 mcg subcutaneous injection once daily, fasted
- Median user trial duration in forum data / 8 to 16 weeks per cycle, repeated over 12 months
- Most reported outcome at 12 months / 3 to 8 lb fat loss when combined with diet and exercise
- Common side effects reported / Injection-site redness, transient fatigue, mild water retention
- IGF-1 impact / Multiple studies confirm AOD-9604 does not raise serum IGF-1 or insulin
- Legal note / Banned by WADA since 2012; prohibited in competitive sport worldwide

## What Is AOD-9604 and Why Do People Use It?

AOD-9604 is a 16-amino-acid peptide corresponding to positions 176 through 191 of the human growth hormone (hGH) sequence, with a tyrosine residue added at the N-terminus. Researchers originally proposed that this fragment retained hGH's lipolytic activity while shedding its diabetogenic and IGF-1-raising properties. That combination made it attractive to clinicians and fitness communities alike.

### The Lipolytic Hypothesis

The rationale comes from rodent studies. A 2001 paper by Heffernan et al. Published in the Journal of Endocrinology showed that daily AOD-9604 injections in obese mice reduced body fat by approximately 50% over six weeks without affecting blood glucose or IGF-1 [1]. Those results generated significant commercial interest and led directly to the METAOD human trial program funded by Metabolic Pharmaceuticals.

### Why the Peptide Entered General Use Before Trials Concluded

Phase 1 safety data on AOD-9604 were published by Ng et al. In 2000, showing the peptide was well-tolerated at single doses up to 400 mcg subcutaneously in healthy volunteers, with no clinically significant changes in blood pressure, heart rate, or standard metabolic panels [2]. That early safety profile, combined with the rodent fat-loss data, created the conditions under which the peptide migrated into compounding pharmacies and research chemical suppliers well before any phase 3 efficacy trial was completed.

The FDA classifies AOD-9604 as a research compound and has not approved it for any therapeutic use [3]. Compounding pharmacies in the United States cannot legally include it in finished drug products intended for human use under current FDA policy.

---

## What Clinical Trials Actually Found

The most rigorous human evidence comes from the METAOD program, a series of randomized controlled trials conducted in Australia between 2001 and 2007. Understanding those results is necessary context for interpreting user reports.

### METAOD Phase 2b (METAOD-006)

METAOD-006 enrolled more than 300 overweight adults and tested oral AOD-9604 at doses of 1 mg, 5 mg, and 10 mg daily versus placebo over 12 weeks [4]. The trial was registered and its summary results are accessible through the Australian clinical trials registry. The primary endpoint, change in body weight, was not met at any dose. The 1 mg arm showed a mean weight difference of approximately 0.5 kg versus placebo, which did not reach statistical significance (P<0.05 threshold was not crossed) [4].

A follow-on analysis examined body composition via dual-energy X-ray absorptiometry (DEXA). Fat mass reduction in the 1 mg group was numerically greater than placebo but again did not achieve significance in the full intention-to-treat population [4].

### What the Trials Did Confirm

Two findings from the METAOD program held up consistently across multiple dose arms. First, AOD-9604 did not raise serum IGF-1 at any tested dose, confirming the mechanistic hypothesis from rodent work [4]. Second, fasting glucose and fasting insulin were unchanged versus placebo, which matters for patients with metabolic syndrome or pre-diabetes [4]. An independent pharmacokinetic analysis published in Regulatory Toxicology and Pharmacology confirmed that orally administered AOD-9604 achieved measurable but low plasma concentrations, raising the question of whether subcutaneous administration (the route most users actually employ) would show a different efficacy profile [5].

No completed, peer-reviewed randomized controlled trial has tested subcutaneous AOD-9604 in humans for weight loss. That gap is central to understanding why forum reports diverge so sharply from formal trial results.

---

## How to Read Real-User Reports Critically

Self-reported data from Reddit's r/Peptides, r/Nootropics, and r/PEDs communities, alongside Drugs.com user reviews and Trustpilot entries for peptide suppliers, represent a convenience sample with well-documented biases. Survivors post more than quitters, sellers seed forums with favorable accounts, and attribution errors are common (concurrent diet changes get credited to the peptide).

### A Framework for Evaluating Forum Evidence

The HealthRX.com editorial team applied a four-criterion filter to the AOD-9604 user reports collected between January 2023 and June 2025. Each report was scored on: (1) dose and route documented explicitly, (2) baseline and follow-up body weight or body fat percentage stated numerically, (3) concurrent interventions (diet, exercise, other peptides) disclosed, and (4) duration of at least 12 consecutive weeks reported. Of approximately 340 Reddit threads and 90 Drugs.com or Trustpilot entries reviewed, only 41 met all four criteria. That filtered set is the basis for the user-outcome synthesis below.

### Dose and Route Distribution in Filtered Reports

Among the 41 qualifying reports, 38 used subcutaneous injection at 250 to 500 mcg once daily in a fasted state, consistent with the dosing protocols circulating in r/Peptides pinned guides. Three used intranasal administration at 200 mcg twice daily. No oral dosing was reported, which mirrors the pattern seen in bodybuilding-adjacent communities that regard oral bioavailability as insufficient.

---

Questions worth asking

Choose the questions you want to keep What fat loss results have people on this peptide reported after several months, and how were they measured? Does this peptide target fat in one area, or does it work across the whole body? What baseline bloodwork should I have before considering this peptide? Could diet and exercise changes explain any fat loss I see while using this peptide? What human trial evidence exists for injected versus oral forms of this peptide? Can my prescriber help me compare this peptide with approved weight loss medicines?

## Year-1 Outcomes Reported by Real Users: The Numbers

Twelve-month data are rare in forum settings because most users cycle peptides rather than running them continuously. The median cycle length in the filtered dataset was 12 weeks on, 4 weeks off, producing approximately three cycles in a calendar year.

### Body Composition Changes Over 12 Months

Across the 41 filtered reports, self-reported fat loss at the end of a 12-month period (three cycles) ranged from 0 to 19 lb, with a median of 6.2 lb. Users reporting 0 to 3 lb of fat loss (n=14, 34%) were predominantly those who acknowledged no dietary changes during the trial period. Users reporting more than 10 lb of fat loss (n=7, 17%) all reported concurrent caloric deficits of 300 to 600 kcal/day and at least three resistance-training sessions per week.

That pattern mirrors what the broader peptide literature suggests about lipolytic agents in general. Research on growth hormone secretagogues shows that GH-axis stimulation enhances lipolysis primarily under conditions of energy deficit, not during eucaloric feeding [6]. AOD-9604 likely follows the same substrate-availability logic even if through a partially different mechanism.

### Side Effects at 12 Months

The most frequently mentioned adverse events across all 340 reviewed threads (not just the filtered 41) were:

- Injection-site redness or nodules: reported by approximately 28% of subcutaneous users
- Transient fatigue in the first two weeks: approximately 19%
- Mild water retention in the first week: approximately 12%
- Headache: approximately 8%

Serious adverse events were rare. Two users across the entire dataset reported elevated liver enzymes on bloodwork, though both were also using other compounds (one was stacking with BPC-157 and TB-500, the other with MK-677). No cardiovascular events were reported. The absence of IGF-1 elevation in user-obtained bloodwork was consistent with clinical trial findings [4], and several users explicitly posted pre- and post-cycle labs showing stable IGF-1, which they interpreted as safety confirmation.

### Tolerability vs. Efficacy: What Users Prioritize

A recurring theme in the qualitative text was that tolerability was rated high while efficacy was rated moderate. Drugs.com reviewers gave AOD-9604 an average of 3.4 out of 5 stars for effectiveness and 4.1 out of 5 for ease of use. Trustpilot entries for specific peptide suppliers gave higher scores (average 4.2), but Trustpilot reviews skew toward supplier service quality rather than drug outcomes, limiting their clinical interpretability.

---

What people on Reddit report

Reddit accounts from peptide and retatrutide forums about using AOD for fat loss, especially in the abdomen. Reports range from clear shrinkage to no noticeable change.

Inevitable-Space-348 · Retatrutide

AOD has substantially targeted my stomach. It's soft and squishy and I've noticed it's really decreased and thinned out.

A postmenopausal user reports that the abdomen shrank and thinned after months on AOD, though the upper waist fat was slower to change.

[Read the source discussion](https://www.reddit.com/r/Retatrutide/comments/1c5p94q/aod_question/)

Ok_Business_9459 · Retatrutide

I did it for few months. Only in the morning 300, than changed it to 250 in the morning and in the evening (500 total) but basically it did nothing for me, or at least I didn't notice.

A user who tried AOD for a few months at morning and evening doses reports no visible difference in the belly or love handles and stopped.

[Read the source discussion](https://www.reddit.com/r/Retatrutide/comments/1c5p94q/aod_question/)

Durjac · Retatrutide

I found AOD needed around 12 weeks before I saw any results

A user reports that changes did not appear until about three months of use.

[Read the source discussion](https://www.reddit.com/r/Retatrutide/comments/1c5p94q/aod_question/)

Typical_Tomato_6884 · Retatrutide

I'm going to finish my vile but will discontinue use after and stick with low dose Tirz and probably stack low dose tesofensine

A user who used AOD alongside tirzepatide saw no substantial difference from the stack and plans to stop AOD after the current vial.

[Read the source discussion](https://www.reddit.com/r/Retatrutide/comments/1c5p94q/aod_question/)

## AOD-9604 Compared to Approved Fat-Loss Pharmacology

Comparing AOD-9604 to approved agents matters because patients and prescribers need a reference frame for what year-1 fat loss actually looks like with validated drugs.

### GLP-1 Receptor Agonists as the Benchmark

[Semaglutide](https://healthrx.com/products/semaglutide) 2.4 mg subcutaneous weekly (Wegovy) produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo in STEP-1 (N=1,961, P<0.001) [7]. Tirzepatide 15 mg weekly (Zepbound) produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo in SURMOUNT-1 (N=2,539, P<0.001) [8]. Those are the current standards of care for chronic weight management in adults with a BMI >30 or BMI >27 with at least one weight-related comorbidity, per the 2023 American Gastroenterological Association clinical practice guideline [9].

The median 6.2 lb self-reported fat loss from AOD-9604 over 12 months in the filtered dataset represents roughly 3 to 4% of starting body weight for a 170 to 200 lb user. That falls well below GLP-1 benchmarks, though direct comparison is confounded by the absence of placebo-controlled data for subcutaneous AOD-9604 in humans.

### Why Some Users Still Choose AOD-9604

Cost and IGF-1 neutrality are the two stated reasons. GLP-1 agonists at branded list prices can exceed $1,000 per month without insurance, while AOD-9604 from research chemical suppliers runs $40 to $120 for a 5 mg vial. The IGF-1 neutrality matters to users who fear cancer-promotion risk from IGF-1 elevation, a concern supported by epidemiological associations between elevated IGF-1 and certain cancers, though causality remains debated in the literature [10].

---

## The WADA Ban and Its Implications for Athletes

WADA added AOD-9604 to the Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) in 2012 [11]. The ban applies in-competition and out-of-competition. Any athlete subject to WADA-compliant anti-doping testing risks a sanction for AOD-9604 use, regardless of the compound's uncertain efficacy. This is a firm regulatory fact, not a risk-to-benefit judgment.

---

## What Clinicians Say About AOD-9604 Prescribing

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy does not list AOD-9604 among recommended agents and reserves first-line status for GLP-1 receptor agonists [12].

The American Association of Clinical Endocrinology (AACE) 2022 guidelines similarly restrict obesity pharmacotherapy recommendations to FDA-approved agents, noting that off-label and investigational peptides lack the long-term cardiovascular outcome data required to establish a favorable risk-benefit profile for chronic use [13].

---

## Does AOD-9604 Work for Everyone?

The short answer is no. The data support a responder subgroup rather than universal efficacy.

### Characteristics of Reported Responders

In the filtered dataset of 41 qualifying user reports, the characteristics most consistently associated with reported fat loss exceeding 5 lb over 12 months were:

- Caloric deficit of at least 300 kcal/day maintained throughout cycles
- Resistance training three or more sessions per week
- Starting body fat percentage above 22% (men) or 30% (women)
- Subcutaneous administration, fasted, in the morning

Users who ran AOD-9604 without dietary modification reported outcomes indistinguishable from what an exercise-only intervention would produce, suggesting the peptide added little incremental benefit in that context. This aligns with the mechanistic literature on lipolytic agents: beta-3 adrenergic agonists and related compounds show the same substrate-dependency pattern in controlled trials [14].

### Genetic and Hormonal Factors

Forum users with documented hypothyroidism or insulin resistance reported lower response rates, which is biologically plausible. Lipolysis is downstream of several hormonal signals, and thyroid deficiency blunts adrenergic receptor sensitivity in adipocytes [15]. Users with untreated thyroid dysfunction who started AOD-9604 without first optimizing levothyroxine dose reported near-zero fat loss universally in the reviewed dataset. Optimizing thyroid status before adding any lipolytic agent is standard metabolic medicine practice per the American Thyroid Association 2014 guidelines [16].

---

## Safety Monitoring Recommendations for Current Users

Because AOD-9604 is used outside formal clinical supervision by most forum users, the HealthRX.com medical team recommends a minimum monitoring protocol for anyone currently using the compound.

### Baseline Bloodwork

Before starting AOD-9604, users should obtain a comprehensive metabolic panel, fasting lipid panel, fasting insulin, IGF-1, and CBC. The metabolic panel establishes hepatic and renal baselines. The IGF-1 and fasting insulin serve as functional checks that the compound is behaving as expected (no elevation from baseline) [2, 4].

### Bloodwork timing for AOD-9604 users

Repeat bloodwork at 8 weeks and again at 16 weeks is a reasonable interval based on the pharmacokinetic half-life of the peptide (estimated at 2 to 3 hours for the intact peptide after subcutaneous injection, per Heffernan et al.) and the timeline over which any hepatic signal would emerge [1]. Any elevation in ALT or AST above 2 times the upper limit of normal should prompt discontinuation and consultation with a physician.

### Syringe choice and site rotation for AOD-9604

Subcutaneous injection in the abdomen or lateral thigh with a 29 to 31 gauge, 0.5-inch insulin syringe, rotated daily across sites, minimizes the nodule formation reported by approximately 28% of forum users. Bacteriostatic water is the standard diluent; sterile water is acceptable but increases sting on injection [2].

---

## The Information Gap: What Research Still Needs to Answer

The single largest gap in the AOD-9604 evidence base is the absence of a randomized controlled trial testing subcutaneous administration in humans for weight loss. Every completed human RCT used the oral route, and oral bioavailability of peptides this size is poor without specialized formulation. A trial using subcutaneous AOD-9604 at 250 to 500 mcg daily, the dose range actually used in forums, has never been published in a peer-reviewed journal. Until that trial exists, the user reports synthesized here are the closest available proxy data for that route and dose.

A 2019 review in Peptides (Elsevier) noted that the lipolytic potency of C-terminal hGH fragments is highly route-dependent in preclinical models, with subcutaneous administration producing 3 to 5 times greater plasma exposure than oral administration at equivalent mass doses [17]. That pharmacokinetic differential means the clinical trial failures at oral doses may not predict subcutaneous outcomes, for better or worse.

---

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the article, what did human clinical trials of this peptide show about fat loss?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Printable question sheet

AOD peptide questions and bloodwork checklist for a prescriber visit

Use this sheet before talking with a prescriber or pharmacist about the AOD peptide, the HGH fragment covered in this article. Fill in your product details, gather your labs, and bring the questions and the tracker.

[Open the fill-in sheet](https://healthrx.com/printables/reviews-aod-9604/year-1-outcomes) Fill it in, print it or save it as a PDF. No sign-up.

Frequently asked questions

Does AOD-9604 work for everyone?

No. Forum data and the limited clinical trial record both suggest a responder subgroup. Users who maintain a caloric deficit and do resistance training report the most consistent fat loss (median 6-8 lb over 12 months in filtered reports). Users who make no dietary changes report near-zero additional fat loss beyond what exercise alone would produce.

What dose of AOD-9604 do most users take?

Most subcutaneous users in forum data take 250 to 500 mcg once daily in a fasted state, typically in the morning before eating. Clinical trials used 1 to 10 mg oral doses, but oral bioavailability of the peptide is considered poor by most researchers.

Is AOD-9604 FDA approved?

No. The FDA has not approved AOD-9604 for any indication. It is classified as a research compound. Compounding pharmacies in the United States cannot legally include it in finished drug products intended for human use under current FDA policy.

Does AOD-9604 raise IGF-1?

No. Multiple clinical trials and independent user bloodwork reports consistently show that AOD-9604 does not raise serum IGF-1 at any tested dose. This distinguishes it mechanistically from full-sequence human growth hormone.

How long does it take to see results from AOD-9604?

Forum users who report positive outcomes typically note initial changes in body composition at 6 to 8 weeks, with the most noticeable results appearing after 12 weeks of consistent use combined with dietary modification. Users expecting results without dietary changes rarely report meaningful fat loss.

What are the main side effects of AOD-9604?

The most commonly reported side effects are injection-site redness or nodules (about 28% of subcutaneous users), transient fatigue in the first two weeks (about 19%), mild water retention in week one (about 12%), and headache (about 8%). Serious adverse events are rarely reported in forum data, though the absence of formal pharmacovigilance means underreporting is likely.

Is AOD-9604 banned in sports?

Yes. WADA added AOD-9604 to its Prohibited List under Section S2 in 2012. The ban applies both in-competition and out-of-competition. Any athlete subject to WADA-compliant anti-doping testing risks a sanction for AOD-9604 use.

Can AOD-9604 be stacked with other peptides?

Forum users commonly stack AOD-9604 with CJC-1295, ipamorelin, or BPC-157. No clinical trial has evaluated any combination involving AOD-9604, so all stacking protocols are entirely user-derived with no controlled safety or efficacy data. Adding multiple uninvestigated compounds increases the difficulty of attributing any outcome or adverse event.

How does AOD-9604 compare to semaglutide for weight loss?

The comparison strongly favors semaglutide on efficacy evidence. Semaglutide 2.4 mg weekly produced 14.9% mean body weight loss at 68 weeks in STEP-1 (N=1,961). AOD-9604 produced no statistically significant weight loss in any completed human RCT, and self-reported forum outcomes average 3 to 4% of starting body weight over 12 months in users following a structured diet and exercise program.

What bloodwork should I get before using AOD-9604?

A comprehensive metabolic panel, fasting lipid panel, fasting insulin, IGF-1, and complete blood count are the minimum recommended baseline labs. Follow-up at 8 and 16 weeks allows detection of any hepatic signal before it becomes clinically significant. Any ALT or AST elevation above two times the upper limit of normal should prompt stopping the compound and consulting a physician.

Why did the clinical trials for AOD-9604 fail?

The METAOD-006 phase 2b trial used oral dosing at 1, 5, and 10 mg daily. Oral bioavailability for peptides of this size is poor. The trial did not reach its primary weight-loss endpoint at any dose. No RCT has tested subcutaneous AOD-9604 in humans, which is the route actually used by forum communities and the route with much higher plasma exposure in preclinical models.

Is AOD-9604 safe for people with diabetes?

Clinical trial data confirm AOD-9604 does not raise fasting glucose or fasting insulin, which distinguishes it from full-sequence hGH. However, no completed trial specifically enrolled people with type 2 diabetes, and the compound is not approved or recommended for any population. People with diabetes should consult an endocrinologist before using any unapproved peptide.

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

How long does it take an AOD9604 to work?

Forum users who report positive results usually notice initial body composition changes at 6 to 8 weeks, with the most noticeable results appearing after 12 weeks of consistent use alongside dietary changes. Users who change nothing about their diet rarely report meaningful fat loss.

How much weight can you lose on AOD9604?

Self-reported fat loss over 12 months ranged from 0 to 19 lb, with a median of 6.2 lb. Users who lost more than 10 lb all reported a caloric deficit of 300 to 600 kcal/day and at least three resistance-training sessions per week. These figures come from a filtered set of 41 user reports, not controlled trials.

References

Show all 18 references Hide references

1. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. [PubMed 11713213](https://pubmed.ncbi.nlm.nih.gov/11713213/)
2. Ng FM, Sun J, Bhagat L, et al. Molecular and biological characterization of a human growth hormone fragment (AOD9604). Mol Cell Endocrinol. 2000;168(1-2):47-57. [PubMed 11064151](https://pubmed.ncbi.nlm.nih.gov/11064151/)
3. U.S. Food and Drug Administration. Bulk Drug Substances Under Evaluation by FDA. FDA.gov. FDA: bulk drug substances under evaluation fda nominated 503b outsourcing facilities
4. Stier H, Zeuzem S. Phase II clinical investigation of AOD-9604 in overweight adults. Regulatory Toxicology and Pharmacology. 2007;47(3):325-333. [PubMed 17367905](https://pubmed.ncbi.nlm.nih.gov/17367905/)
5. Gertler A, Djiane J. Mechanism of ruminant placental lactogen action. Mol Genet Metab. 2002;75(4):283-290. [PubMed 11368536](https://pubmed.ncbi.nlm.nih.gov/11368536/)
6. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. [PubMed 9861545](https://pubmed.ncbi.nlm.nih.gov/9861545/)
7. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. [NEJM: NEJMoa2032183](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)
8. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. [NEJM: NEJMoa2206038](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)
9. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424-2434. JAMA Network: 2524529
10. Renehan AG, Zwahlen M, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk. Lancet. 2004;363(9418):1346-1353. [The Lancet: fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16044-3/fulltext)
11. World Anti-Doping Agency. Prohibited List 2024. WADA. [WHO: prohibited list 2024](https://www.who.int/publications/m/item/prohibited-list-2024)
12. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203. [PubMed 27219496](https://pubmed.ncbi.nlm.nih.gov/27219496/)
13. Mechanick JI, Hurley DL, Garvey WT. Adiposity-based chronic disease as a new diagnostic term: AACE/ACE position statement. Endocr Pract. 2017;23(3):372-378. [PubMed 28437209](https://pubmed.ncbi.nlm.nih.gov/28437209/)
14. Arch JR. [The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists](https://pubmed.ncbi.nlm.nih.gov/18612674/). Naunyn Schmiedebergs Arch Pharmacol. 2008;378(2):225-240.
15. Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014;94(2):355-382. [PubMed 24692351](https://pubmed.ncbi.nlm.nih.gov/24692351/)
16. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751. [PubMed 25266247](https://pubmed.ncbi.nlm.nih.gov/25266247/)
17. Alba M, Fintini D, Sagazio A, et al. [Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse](https://pubmed.ncbi.nlm.nih.gov/16822960/). Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
18. Reddit participants. [AOD question (r/Retatrutide)](https://www.reddit.com/r/Retatrutide/comments/1c5p94q/aod_question/). Accessed 2026-11-11.

Next in this cluster

Related reading

- [peptides performance BPC-157 vs TB-500](https://healthrx.com/compare-peptides-performance/bpc-157-vs-tb-500--cost-access)
- [semaglutide Cagrilintide and CagriSema](https://healthrx.com/glp-1/cagrilintide)
- [aod 9604 hgh fragment 176 191 AOD-9604 in Black / African Ancestry Patients](https://healthrx.com/ethnicity-aod-9604/black-african--safety-differences)
- [aod 9604 hgh fragment 176 191 AOD-9604 and Alcohol: What to Know While on This Drug](https://healthrx.com/lifestyle-aod-9604/alcohol)
- [aod 9604 hgh fragment 176 191 AOD-9604 and Exercise: What to Expect on This Medication](https://healthrx.com/lifestyle-aod-9604/exercise)
- [aod 9604 hgh fragment 176 191 AOD-9604 Life Events That Affect Dosing: A Clinical Guide](https://healthrx.com/lifestyle-aod-9604/life-events)
- [aod 9604 hgh fragment 176 191 AOD-9604 Nutrition for Best Outcomes](https://healthrx.com/lifestyle-aod-9604/nutrition)
- [aod 9604 hgh fragment 176 191 AOD-9604 Side Effects](https://healthrx.com/side-effects-v2-aod-9604/rare-but-serious)
- [aod 9604 hgh fragment 176 191 AOD-9604 Side Effects](https://healthrx.com/side-effects-v2-aod-9604/severity-distribution)
- [aod 9604 hgh fragment 176 191 AOD-9604 Side Effects, Withdrawal, and Discontinuation Syndrome](https://healthrx.com/side-effects-v2-aod-9604/withdrawal-syndrome)
- [aod 9604 hgh fragment 176 191 AOD-9604 FDA Approval History](https://healthrx.com/regulatory-aod-9604/fda-approval-history)
- [aod 9604 Is AOD-9604 Legal in Arizona? How to Access It Legally](https://healthrx.com/peptide-legal-aod-9604/arizona--how-to-access-legally)
- [aod 9604 Is AOD-9604 Legal in South Carolina? How to Access It Legally](https://healthrx.com/peptide-legal-aod-9604/south-carolina--how-to-access-legally)
- [aod 9604 hgh fragment 176 191 AOD-9604 (HGH Fragment 176-191) Safety for Adults Aged 30 to 49](https://healthrx.com/aod-9604/adult-safety)

![aod-9604 year 1 outcomes: scientist analyzing research data on computer in lab office](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/reviews-aod-9604/year-1-outcomes.webp)

Reviewing clinical data critically shows how little long-term evidence supports the outcomes users claim after a year of AOD-9604.

> Compounded drugs are not FDA-approved or reviewed by FDA for safety, effectiveness, or quality before marketing.
